Navigation Links
Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/19/2008

domestic) or 617-213-4867 (international). The passcode for the conference call is 82632306. Participants may pre-register for the call at: https://www.theconferencingservice.com/prereg/key.process?key=RGRXWMYHV

A telephone replay of the call will also be available for 48 hours. Callers may access the telephone replay by dialing (domestic) 888-286-8010 or 617-801-6888 (international), passcode 10008184.

About Community Acquired Pneumonia (CAP)

CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Approximately 5.6 million cases of CAP are diagnosed each year in the United States with 10 million physician visits, resulting in an estimated total annual expenditure of $2 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not treated properly, and the bacteria that cause CAP are developing resistance to current standard of care treatments.

Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.

About Cethromycin

Cethromycin has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalati
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... EUGENE, Ore. -- Scientists, including University of Oregon ... to create scaffolds of self-assembling, synthetic proteins called ... processes. , The accomplishment -- detailed this week ... by the Proceedings of the National Academy ... an alternative design of the two-dimensional peptoid nanosheets ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... remediation provides environmentally friendly alternative to currently used chemicals.ATLANTA, ... ("EAU" or "Company") (OTC Bulletin Board: EAUI), a ... receipt of Patent #US7,445,800 B2, from the United States ... Primacide A and C for mold remediation. ...
... Wis., Jan. 22 Mach One Corporation,(Pink Sheets: MNCN), ... positive long term benefit to the agricultural and consumer,market, ... Swap of,$1.5 million with an Investor. , ... facilitate the equipment purchase for,its first production facility in ...
... Infrequent, Every Twelve-Week Maintenance DosingBEERSE, Belgium, Jan. 22 ... first in a new class of biologics, has been ... The approved indication of ustekinumab is for the ... who failed to respond to, or who have a ...
Cached Biology Technology:EAU Technologies Receives Patent for Empowered Water(TM) 2EAU Technologies Receives Patent for Empowered Water(TM) 3EAU Technologies Receives Patent for Empowered Water(TM) 4Mach One Completes Note Exchange 2New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 2New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 3New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 4
(Date:9/2/2014)... breast milk is considered the most ideal source ... played a critical role in the evolution and ... human milk contains a large number of bacterial ... phenomenon comes as no surprise to scientists and ... is considered to be the result of co-evolutionary ...
(Date:9/2/2014)... integrity? Tell the truth; everyone has a tipping point. We ... lie if the benefit is great enough. Now, scientists have ... that decision. , The result was published online this ... prefer to be honest, even if lying is beneficial," said ... at the Virginia Tech Carilion Research Institute , where ...
(Date:9/2/2014)... With their long, spiky legs and their propensity for ... stuff of nightmares. And now research from North Carolina ... spread into homes across the eastern United States. , ... or pose any kind of threat to humans," says ... State and lead author of a paper about the ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... Lowers blood pressure, encourages exercise, improves psychological health ... drug, but they are actually among the benefits of ... of Missouri College of Veterinary Medicine Research Center for ... benefit people of all ages during the International Society ...
... pregnancies are less likely to occur. Life ... Virginia J. Vitzthum, a senior scientist at Indiana University,s ... and professor in the IU College of Arts and ... of intense labor and low food intake, rates of ...
... Exposure to light and possibly photosynthesis itself could be ... them impervious to washing, according to research published in the ... . Salmonella enterica is a common cause ... 3 million human cases per year in the United States. ...
Cached Biology News:A pet in your life keeps the doctor away 2A pet in your life keeps the doctor away 3Studies examine how living conditions impact reproductive health 2Light, photosynthesis help bacteria invade fresh produce 2
... The Fujifilm Life Science FLA-8000 Fluorescent Image ... in a single laser imaging system. This ... samples labeled with fluorescent dyes or radioisotopes ... most demanding laboratories. Speed, image quality and ...
...
...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
Biology Products: